protein

Recombinant Human Vascular Endothelial Growth Factor receptor-3 Fc Chimera

MBS142791

0.002 mg

140 USD

Recombinant Protein

Recombinant Human Vascular Endothelial Growth Factor receptor-3 Fc Chimera

Vascular Endothelial Growth Factor receptor-3 Fc Chimera

FLT4 Fc Human; Vascular Endothelial Growth Factor Receptor-3 Fc Chimera Human Recombinant; Tyrosine-protein kinase receptor FLT4; PCL; FLT41; FMS-LIKE TYROSINE KINASE 4; VEGFR-3; FLT4 Fc

vascular endothelial growth factor receptor 3 isoform 2; Vascular endothelial growth factor receptor 3; vascular endothelial growth factor receptor 3; FLT-4; VEGFR-3; fms-like tyrosine kinase 4; soluble VEGFR3 variant 1; soluble VEGFR3 variant 2; soluble VEGFR3 variant 3; tyrosine-protein kinase receptor FLT4; fms-related tyrosine kinase 4; Fms-like tyrosine kinase 4; FLT-4; Tyrosine-protein kinase receptor FLT4

FLT4

FLT4; FLT4; PCL; FLT41; LMPH1A; VEGFR3; VEGFR3; VEGFR-3; FLT-4

VGFR3_HUMAN

Insect Cells

1298

Greater than 90.0% as determined by(a)Analysis by RP-HPLC. (b)Analysis by SDS-PAGE.

FLT4 Fc Chimera was lyophilized from a concentrated (1 mg/ml) sterile solution containing no additives. Sterile Filtered White lyophilized (freeze-dried) powder.

Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18 degree C. Upon reconstitution FLT4 should be stored at 4 degree C between 2-7 days and for future use below -18 degree C.For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Please prevent freeze-thaw cycles.

Solubility: It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 ug/ml, which can then be further diluted to other aqueous solutions. Biological Activity: Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 ug/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml.

PROTEIN KINASES; Enzymes; VEGF Receptors

Description: Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids and having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Introduction: All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases (RTKs) characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular and lymphatic endothelial cells and to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis and lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain and a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C and VEGF-D have been shown to bind and activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis.

103472027

NP_002011.2

NM_002020.4

P35916

93,174 Da

Cytokine-cytokine Receptor Interaction Pathway (83051); Cytokine-cytokine Receptor Interaction Pathway (460); Focal Adhesion Pathway (83067); Focal Adhesion Pathway (478); PI3K-Akt Signaling Pathway (692234); PI3K-Akt Signaling Pathway (692979); Rap1 Signaling Pathway (868086); Rap1 Signaling Pathway (878042); Ras Signaling Pathway (868085); Signal Transduction Pathway (477114)

This gene encodes a tyrosine kinase receptor for vascular endothelial growth factors C and D. The protein is thought to be involved in lymphangiogenesis and maintenance of the lymphatic endothelium. Mutations in this gene cause hereditary lymphedema type IA. [provided by RefSeq, Jul 2008]

VEGFR3: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced production of VEGFC, and to a lesser degree VEGFA, thereby creating a positive feedback loop that enhances FLT4 signaling. Modulates KDR signaling by forming heterodimers. The secreted isoform 3 may function as a decoy receptor for VEGFC and/or VEGFD and play an important role as a negative regulator of VEGFC-mediated lymphangiogenesis and angiogenesis. Binding of vascular growth factors to isoform 1 or isoform 2 leads to the activation of several signaling cascades; isoform 2 seems to be less efficient in signal transduction, because it has a truncated C-terminus and therefore lacks several phosphorylation sites. Mediates activation of the MAPK1/ERK2, MAPK3/ERK1 signaling pathway, of MAPK8 and the JUN signaling pathway, and of the AKT1 signaling pathway. Phosphorylates SHC1. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3- kinase. Promotes phosphorylation of MAPK8 at Thr-183 and Tyr- 185 , and of AKT1 at Ser-473 . Interacts with VEGFC and VEGFD. Monomer in the absence of bound VEGFC or VEGFD. Homodimer in the presence of bound VEGFC or VEGFD. Can also form a heterodimer with KDR. Interacts with PTPN14; the interaction is enhanced by stimulation with VEGFC. Interacts with CRK, GRB2, PTK2/FAK1, SHC1, PIK3R1 and PTPN11/SHP- 2. Identified in a complex with SRC and ITGB1. Detected in endothelial cells. Widely expressed. Detected in fetal spleen, lung and brain. Detected in adult liver, muscle, thymus, placenta, lung, testis, ovary, prostate, heart, and kidney. Present in an inactive conformation in the absence of bound ligand. Binding of VEGFC or VEGFD leads to dimerization and activation by autophosphorylation on tyrosine residues. Inhibited by MAZ51. Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily. 3 isoforms of the human protein are produced by alternative splicing. Protein type: EC 2.7.10.1; Protein kinase, TK; Membrane protein, integral; Kinase, protein; Protein kinase, tyrosine (receptor); TK group; VEGFR family. Chromosomal Location of Human Ortholog: 5q35.3. Cellular Component: integral to plasma membrane; cytoplasm; extracellular region; plasma membrane; nucleus; receptor complex. Molecular Function: vascular endothelial growth factor receptor activity; protein binding; growth factor binding; transmembrane receptor protein tyrosine kinase activity; protein phosphatase binding; ATP binding. Biological Process: peptidyl-tyrosine phosphorylation; protein amino acid autophosphorylation; positive regulation of JNK cascade; positive regulation of MAPKKK cascade; vasculature development; positive regulation of cell proliferation; lymphangiogenesis; blood vessel morphogenesis; positive regulation of endothelial cell proliferation; positive regulation of protein amino acid phosphorylation; sprouting angiogenesis; lymph vessel development; vascular endothelial growth factor receptor signaling pathway; transmembrane receptor protein tyrosine kinase signaling pathway; negative regulation of apoptosis. Disease: Hemangioma, Capillary Infantile; Lymphedema, Hereditary, Ia

0.002 mg

140 USD

0.01 mg

205

1 mg

4820